Recent and expected drug approvals to widen interest in wAMD market

9 April 2022

A flourish of activity in the wet age-related macular degeneration (wAMD) market, coupled with anticipated approvals of other products - particularly biosimilars - is expected to widen interest in the AMD market among stakeholders, says analyst.

According to data and analytics firm GlobalData’s pharmaceutical analyst Vinie Varkey: "The wAMD market is on the precipice of a wave of new products. GlobalData’s Pharmaceutical Intelligence Centre (PIC) reveals that there are currently 15 products in late-stage development that are exclusively for wAMD in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan).

The majority of these products fall either into the category of anti-vascular endothelial growth factor (VEGF) therapy, a drug class that is well-established for wAMD, or are biosimilars. In terms of innovation, RGX-314 from RegenxBio (Nasdaq: RGNX) and AbbVie (NYSE: ABBV) is a gene-therapy that has the potential to be used as a one-time treatment option for patients with wAMD."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK